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 i g  h  l  i  g  h  t  s
• Genetic  variation  can  inﬂuence  response  to antiepileptic  drug  (AED)  treatment  through  various  effector  processes.
• Metabolism  of  many  AEDs  is mediated  by  the  cytochrome  P450  (CYP)  family;  some  of  the  CYPs  have  allelic  variants  that  may  affect  serum  AED
concentrations.
• ‘Precision  medicine’  focuses  on  the identiﬁcation  of an underlying  genetic  aetiology  allowing  personalised  therapeutic  choices.
• Certain  human  leukocyte  antigen,  HLA,  alleles  are  associated  with  an increased  risk  of  idiosyncratic  adverse  drug  reactions.
• New  results  are  emerging  from  large-scale  multinational  efforts,  likely  imminently  to  add  knowledge  of  value  from  a  pharmacogenetic  perspective.
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a  b  s  t  r  a  c  t
There  is  high  variability  in  the response  to antiepileptic  treatment  across  people  with  epilepsy.  Genetic
factors  signiﬁcantly  contribute  to such  variability.  Recent  advances  in  the  genetics  and  neurobiology
of  the epilepsies  are  establishing  the  basis  for a  new era  in the  treatment  of epilepsy,  focused  on  each
individual  and  their  speciﬁc  epilepsy.  Variation  in  response  to  antiepileptic  drug  treatment  may  arise
from  genetic  variation  in a range  of gene  categories,  including  genes  affecting  drug  pharmacokinetics,
and  drug  pharmacodynamics,  but also  genes  held  to actually  cause  the epilepsy  itself.
From  a purely  pharmacogenetic  perspective,  there  are  few  robust  genetic  ﬁndings  with  established
evidence  in  epilepsy.  Many  ﬁndings  are  still  controversial  with  anecdotal  or less  secure  evidence  and
need  further  validation,  e.g.  variation  in  genes  for  transporter  systems  and  antiepileptic  drug targets.
The  increasing  use  of  genetic  sequencing  and the results  of  large-scale  collaborative  projects  may  soon
expand  the  established  evidence.
Precision  medicine  treatments  represent  a growing  area  of  interest,  focussing  on  reversing  or  cir-harmacogenomics
cumventing  the  pathophysiological  effects  of  speciﬁc  gene  mutations.  This  could  lead  to a  dramatic
improvement  of  the effectiveness  and  safety  of  epilepsy  treatments,  by  targeting  the  biological  mecha-
nisms responsible  for epilepsy  in  each  speciﬁc  individual.
Whilst  much  has  been  written  about  epilepsy  pharmacogenetics,  there  does  now  seem to be  building
momentum  that promises  to  deliver  results  of use  in clinic.
©  2017  The  Authors.  Published  by  Elsevier  Ireland  Ltd.  This  is an open  access  article  under  the  CC  BY
license  (http://creativecommons.org/licenses/by/4.0/).
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. Introduction
The response, in terms both of seizure control and adverse reac-
ions (ADRs), to antiepileptic drugs (AEDs) varies greatly across
ndividuals [1]. Moreover, AED treatment in epilepsy is compli-
ated because there are many different syndrome and seizure
ypes within epilepsy, the biology of almost all of which is largely
nknown. Response rates do seem to vary in relation to epilepsy
yndrome, underlying cause, and other factors [2,3]. The broad phe-
otypic spectrum and heterogeneous aetiology make the choice of
reatment both challenging and empirical: evidence-based infor-
ation guiding clinicians on the most effective drug and dose for
ndividual patients is lacking. Furthermore, AEDs can have many
ssociated ADRs, some of which are severe and life-threatening [4].
 cross-sectional survey of 809 patients showed that 36.5% expe-
ienced one or more ADRs; these events were not related to the
umber of AEDs, but rather to individual susceptibility, the speciﬁc
ED used and physicians’ skills [5].
There is established evidence that genetic factors certainly con-
ribute to this variability [6]. However, few robust ﬁndings have
learly emerged in epilepsy. Progress since the most recent compre-
ensive reviews [6,7] has been limited. The increasing application
f massively-parallel genetic sequencing and results of collabora-
ive projects (such as EpiPGX, http://www.epipgx.eu/and CPNDS,
ttp://cpnds.ubc.ca/) may  soon expand knowledge in this area.
Recent advances in the genetics and neurobiology of the epilep-
ies are establishing the basis for a new era in the treatment of
pilepsy, focused on each individual and their particular epilepsy.
esting for gene variations that might predict drug response and
DRs will hopefully soon improve the efﬁcacy and safety of epilepsy
herapies, targeting the best drug from those available for each indi-
idual patient. Increasing knowledge of the biology of the epilepsies
ay  also lead to the re-purposing for epilepsy of drugs not origi-
ally intended for use in epilepsy, and may  also direct discovery
f rational new therapies. Moreover, as more is becoming under-
tood, it is also clear that in some cases, there is important overlap
etween disease causation and the proﬁle of response to AEDs.
There remains much to be learnt about epilepsy pharma-
ogenomics: any classiﬁcation is necessarily arbitrary. Here, we
istinguish the inﬂuence of genetic factors on response to AEDs
rom those affecting adverse drug reaction. We  further classify the
ormer according to the mediating mechanisms: pharmacokinetics
nd pharmacodynamics, or genes mutations which are recognised
s capable of causing epilepsy (‘epilepsy genes’). This should be
onsidered as an evolving classiﬁcation. Despite ongoing progress
n the ﬁeld, only some ﬁndings are accepted within the community
o far, whilst many results have not been replicated, and might
e speciﬁc to certain populations. Below, we present the state of
he art, by reporting ﬁrst the ﬁndings with the best established
vidence, followed by those with less certain status.Please cite this article in press as: S. Balestrini, S.M. Sisodi
http://dx.doi.org/10.1016/j.neulet.2017.01.014
.1. Inﬂuence of genetic factors on response to AEDs
Genetic variation can inﬂuence response to AEDs through var-
ous mediating effector systems, including pharmacokinetics and . . . .  . .  .  .  . . .  . .  .  . . . . . . .  . . . . .  . . .  . .  . . . . . .  . .  .  . . .  .  .  . .  . . .  .  .  .  . .  .  .  .  .  . . . .  . . . . .  .  . .  .  .  .  . .  00
pharmacodynamics (e.g. polymorphism in gene encoding drug
metabolizing enzymes or putative brain AED targets, such as recep-
tors or ion channels), and mutations in ‘epilepsy genes’; and
by modifying the expression of enzymes and other molecules
involved in the pathogenesis of pharmacoresistance or adverse
drug reactions [8,9]. A key problem is that the mechanistic basis of
pharmacoresistance, especially resistance to multiple AEDs, is not
understood in the vast majority of cases; nor is the overlap between
drug resistance and disease causation well understood [10].
1.2. Pharmacokinetics and pharmacodynamics
In humans, metabolism of those AEDs that undergo such pro-
cesses is mostly mediated by the cytochrome P450 (CYP) family.
Some of the CYPs have genetic (allelic) variants, encoding isoforms
of differing activity, which in turn may  affect serum AED concen-
trations, or alter ﬂux through paths for drug metabolism, with
subsequent potential risk of drug toxicity.
2. Established evidence
There is established evidence of an effect of polymorphic CYP2C9
and CYP2C19 genes: variant alleles can lead to signiﬁcant differ-
ences in AED serum concentrations [11]. CYP2C9 accounts for about
90% of the metabolism of phenytoin. CYP2C9 polymorphisms are
an important determinant of the rate of phenytoin metabolism.
Individuals carrying CYP2C9 alleles encoding variant enzymes
(allozymes) with reduced activity metabolize phenytoin at a con-
siderably slower rate compared with individuals homozygous for
the wild-type (CYP2C9*1; rs1057910(A)) allele, and therefore have a
greater risk of developing concentration-dependent neurotoxicity:
CYP2C9*2 (rs1799853) and CYP2C9*3 (rs1057910(C)) are the best
documented [12,13]. The maximum dose of phenytoin reported in
a series of people with epilepsy was about 50 mg  less per CYP2C9*3
allele [14].
A genome-wide association study of cases with phenytoin-
related severe cutaneous adverse reactions and 412 population
controls from Taiwan discovered a cluster of 16 single nucleotide
polymorphisms in CYP2C genes at 10q23.33 that reached genome-
wide signiﬁcance. Direct sequencing of CYP2C9 identiﬁed missense
variant rs1057910 (CYP2C9*3)  as showing signiﬁcant associa-
tion with phenytoin-related severe cutaneous adverse reactions
[15]. The mechanism underlying this association has yet to be
established. Despite the available evidence, pre-treatment pharma-
cogenetic testing for CYP2C9 variants is not routine practice, with
monitoring for clinical signs of toxicity and serum drug level being
the standard approach.
3. Less robust evidence
Few, and mostly preliminary, data are available on genetic fac-ya, Pharmacogenomics in epilepsy, Neurosci. Lett. (2017),
tors inﬂuencing the metabolism of other AEDs.
Studies investigated the association between CYP2C19
genotypes and the pharmacokinetics of clobazam and N-
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etabolite that reaches higher serum concentrations than
lobazam [16]. CYP2C19 polymorphisms were associated with the
erum concentration of N-clobazam and with clinical efﬁcacy,
hus indicating a gene-dose effect [17–21]. These were conducted
ostly in Asian populations, and have not been replicated more
idely.
Genetic inﬂuences on phenobarbital metabolism seem to relate
ostly to CYP2C19 polymorphism, with ethnic differences in the
olerability proﬁle of phenobarbital [22]. However, there is absence
f evidence that genotyping improves the outcome of phenobar-
ital therapy compared with clinical observation and serum drug
oncentration monitoring.
Valproate (VPA) is subject to complex oxidative and non-
xidative metabolic pathways. The majority of the drug is elim-
nated as glucuronide conjugates. Mitochondrial beta–oxidation,
roducing unsaturated metabolites, is the second major metabolic
athway. About 15–20% of the VPA dose is metabolized by
YP enzymes, resulting in the formation of 4–ene-VPA and
ydroxy-metabolites [23]. The main enzyme for hydroxylation and
esaturation to 4-ene-VPA is CYP2C9, with minor contributions
rom CYP2A6 and CYP2B6 [24].
Lamotrigine is eliminated almost entirely by glucuronidation. A
revious pharmacokinetic study [25] found that in seven individ-
als with Gilbert’s syndrome (unconjugated hyperbilirubinaemia
ue to genetically-determined deﬁciency in uridine diphosphate
lucuronosyltransferase, UGT), lamotrigine clearance was lower
han in healthy controls. The pharmacogenetic impact of this in
pilepsy is unknown.
Zonisamide is eliminated via renal excretion of the 2-
ulfamoylacetyl-phenol (SMAP)-glucuronide (50%), native
nchanged form (35%) and N-acetyl zonisamide (15%) [26].
n vitro data showed that the formation of SMAP is catalyzed
ainly by CYP3A4 and to a minor extent by CYP3A5 and CYP2C19
27]. Okada et al. [28] found that CYP2C19 genotypes may  inﬂuence
he pharmacokinetics of zonisamide, with a role in the develop-
ent of some adverse reactions, in Japanese patients with epilepsy.
gain, these ﬁndings need replication.
Carbamazepine is extensively metabolized in the liver, with
ess than 5% of an oral dose excreted unchanged in urine [29].
arbamazepine is predominantly metabolized to carbamazepine-
0,11-epoxide by CYP3A enzymes. The main enzyme involved in its
etabolism, CYP3A4, has a high number of known polymorphisms
lthough most have a very low frequency and do not reﬂect signif-
cant inter-individual variability in the phenotypic effect in vivo
30]. Carbamazepine-10,11-epoxide and carbamazepine- 10,11-
rans-diol are the primary (≤ 60%) metabolites in urine [31]. Many
YP enzymes are involved in the formation of carbamazepine
etabolites [32] but no signiﬁcant contribution of CYP genotypes
o the pharmacokinetics of carbamazepine has been demon-
trated so far. Single nucleotide polymorphisms of the microsomal
poxide hydrolase (EPHX1) gene have been shown to affect car-
amazepine pharmacokinetics in Chinese people with epilepsy
33], and in Kosovan people with epilepsy of Albanian ethnicity
34].
A further series of reports are all in need of replication.
etigabine is metabolized by extensive N-glucuronidation and
-acetylation. However, its clearance seems not to be affected
n Gilbert’s syndrome nor by common N-acetyl-transferase type
 (NAT-2) polymorphisms [35]. A study in Han Chinese people
ith epilepsy found an association between the effects of SCN1A,
BCC2 and UGT2B7 genetic polymorphisms and oxcarbazepine
aintenance doses [36]. Genetic contribution of CYP1A1 allelesPlease cite this article in press as: S. Balestrini, S.M. Sisodi
http://dx.doi.org/10.1016/j.neulet.2017.01.014
n treatment outcome in people with epilepsy was studied in an
ndian population. In particular, the variant rs2606345 (resulting
n reduced CYP1A1 expression) was associated with poor response
o ﬁrst-line AEDs in Indian women with epilepsy [37,38]. PRESS
nce Letters xxx (2017) xxx–xxx 3
4. Unclear evidence
Drug transporters are involved in the protection of cells and
organs through active extrusion of xenotoxins, including many
drugs. Several ATP-dependent transport proteins have been asso-
ciated with drug resistance. One of the best studied transporters
is P-glycoprotein (P-gp), encoded by the ATP-binding cassette sub-
family B member 1 gene, ABCB1 [39]. In the brain, P-gp is expressed
in astrocytes, endothelial cells and neurons, and there is evidence
that its overexpression in epileptogenic tissue can contribute to
AED resistance [40]. Several studies have demonstrated a link
between ABCB1 gene variants and the response to treatment in
epilepsy, but most studies have in fact been inconclusive [41–44].
A recent meta-analysis including 8,604 subjects from 30 stud-
ies identiﬁed a signiﬁcant correlation between the ABCB1 C3435T
polymorphism and drug-resistant epilepsy, a result that needs to
be veriﬁed in a case-control study with a larger sample size, as
acknowledged by the authors [45]. Evidence for an association
of ABCB1 polymorphisms with AED resistance is still unclear and
does not justify routine testing to predict response to AED ther-
apy.
There have been associations reported for variation in other
transporter-encoding genes and treatment-resistant epilepsy
[36,46–48], but the strength of evidence is less still than that for
ABCB1.
Research into polymorphisms affecting genes encoding AED
targets, such as voltage-gated ion channels [49,50], the GABA-A
receptor [51], or synaptic vesicle proteins [52], has not found any
signiﬁcant association with drug response [53]. More data are likely
to emerge in this area as large consortia sequencing large numbers
of people with epilepsy report their ﬁndings.
4.1. Epilepsy genes
‘Precision medicine’ is an approach for disease treatment and
prevention based on individual variability in genes, environment,
and lifestyle for each person [54]. This approach, incorporating the
identiﬁcation of an underlying genetic aetiology to allow person-
alised therapeutic choice, or to drive re-purposing of drugs, builds
upon thoughtful clinical practice that has been applied for years.
The ‘precision medicine’ paradigm has become more realistic with
advances in discovery of more of the putative causes of epilepsy in
individual patients, and with the wider availability of the necessary
genetic technologies [9,55,56]. Formal quantitative evaluation of
environmental variables is still largely unaddressed, whilst lifestyle
issues have always featured in any holistic approach to the delivery
of care.
In epilepsy, if a speciﬁc gene mutation causes a functional alter-
ation of physiological systems involved in the control of brain
excitability, a rational treatment strategy might ideally aim to
reverse or circumvent the dysfunction. This approach may  not
always prove successful, however, for a number of reasons, includ-
ing the fact that no causal variant acts in isolation, but does so
in the context of the rest of the genome and its variation, and
because compensatory and adaptive changes may become ﬁxed
and difﬁcult, or impossible, to reverse with treatment of the per-
ceived original fault. The current targeted treatment approach
in precision medicine requires the identiﬁcation of the underly-
ing causative genetic alteration, determination of the functional
alteration of the physiological system caused by the genetic
mutation, and evaluation of the effect of treatment putativelyya, Pharmacogenomics in epilepsy, Neurosci. Lett. (2017),
intended and able to reverse or inhibit the functional alter-
ation.
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. Established evidence
An established example of the application of the precision
edicine concept is in the management of GLUT-1 deﬁciency, a
enetic metabolic encephalopathy due to mutations in the SLC2A1
ene, which encodes the glucose type I transporter (GLUT-1),
esulting in impaired transport of glucose across the blood-brain
arrier. GLUT-1 deﬁciency shows wide phenotypic pleiotropy,
ncluding intellectual disability, movement disorder, and drug-
esistant epilepsy, as AEDs usually fail to control seizures. The gold
tandard treatment is the ketogenic diet, which provides ketones
s an alternative fuel for cerebral metabolism, thereby treating the
ymptoms of neuroglycopenia [57]. Early diagnosis and initiation of
etogenic diet are crucial to provide brain nourishment and control
eizures [58], although the beneﬁt on neurodevelopment seems
ontroversial [59]. The challenge is to think of GLUT-1 deﬁciency as
 possible diagnosis, an issue shared by many genetic diagnoses in
pilepsy because of the pleiotropic manifestations of many mutated
enes: the use of gene panels or more extensive sequencing (exome
r genome) can help overcome this difﬁculty.
Pyridoxine (vitamin B6)-dependent epilepsy is caused by bi-
llelic mutations in the ALDH7A1 gene, which encodes antiquitin.
eﬁciency of antiquitin causes seizures because accumulating
1-piperideine-6-carboxylate (P6C) condenses with pyridoxal 5′-
hosphate (PLP) and inactivates this enzyme cofactor, which is
ssential for normal metabolism of neurotransmitters. ALDH7A1
nalysis could also be used for prenatal diagnosis of pyridoxine-
ependent epilepsy and seizures are often fully controlled by
reatment with pyridoxine [60]. B6-responsive seizures may  also be
ue to mutations in pyridox(am)ine 5’-phosphate oxidase (PNPO)
ene, and in some cases may  be better treated with pyridoxal 5′-
hosphate [61].
. Less robust evidence
Other recent reports hint at the potential relevance of precision
edicine in epilepsy, by investigating the effect of treatment of the
olecular defects resulting from speciﬁc mutation in certain genes.
here are few examples so far and most are anecdotal.
Dravet Syndrome is a severe epilepsy syndrome of early child-
ood, associated with drug resistance, developmental slowing or
egression and intellectual disability, and risk of premature mor-
ality, including sudden unexpected death in epilepsy (SUDEP). It
s perhaps the best understood genetic epilepsy and has advanced
nderstanding not only of concepts in disease biology, but also
f treatment biology and genetics. The most frequent cause of
ravet Syndrome is mutation in the voltage-gated sodium chan-
el alpha1 subunit gene (SCN1A). Mutations in SCN1A are also
ssociated with milder phenotypes, such as genetic epilepsy with
ebrile seizures plus (GEFS + ) [62]. Though of all the epilepsies
especially the non-metabolic ones), we understand Dravet Syn-
rome the best, its pathophysiology has not been fully explained
et and this makes the development of targeted treatment more
omplicated. The “interneurone hypothesis” is currently the best-
upported pathophysiological explanation of Dravet Syndrome.
ccording to this hypothesis, SCN1A mutation results in reduced
unction of GABAergic inhibitory interneurons, leading to an over-
ll excessive neuronal excitation [63–65]. However, other studies
sing Dravet Syndrome patient-derived induced pluripotent stem
ells (iPSC) found increased excitability of both GABAergic and
lutamatergic isolated neurons [66]. A recent study identiﬁed aPlease cite this article in press as: S. Balestrini, S.M. Sisodi
http://dx.doi.org/10.1016/j.neulet.2017.01.014
epolarizing GABA phenomenon, and explored the mechanism of
ction of benzodiazepines and stiripentol, commonly beneﬁcial
n Dravet Syndrome, by using a physiology-based computational
odel [67]. It is still unclear if major manifestations of the disease PRESS
nce Letters xxx (2017) xxx–xxx
are caused by disturbances in embryonic development or by persis-
tent SCN1A deﬁciency in later life. It is also not known if increasing
SCN1A expression after birth would alter the disease phenotype. A
recent study demonstrated a new regulatory mechanism of SCN1A
expression, by targeting a long non-coding RNA, both in vitro and in
vivo, in the brain of Dravet knock-in mouse model and a non-human
primate (African green monkey model); upregulation of haploin-
sufﬁcient SCN1A expression led to signiﬁcant improvements in
seizure phenotype and excitability of hippocampal interneurons
[68]. As a paradigmatic epileptic encephalopathy, Dravet Syndrome
still has much to teach us.
Currently, treatment of Dravet Syndrome typically involves
polytherapy with valproate, clobazam and often stiripentol. Evi-
dence for many drugs favoured in Dravet Syndrome is in fact sparse
[69]. Stiripentol is the only compound to have efﬁcacy in Dravet
Syndrome formally demonstrated in a randomised controlled trial
(when combined with valproate and clobazam; [70]); however,
the use of stiripentol, valproate and clobazam does not always
yield complete seizure freedom and may  cause adverse side effects
[71,72]. New and effective treatment strategies with possibly novel
mechanisms are therefore needed.
Many model systems have been employed to explore the cel-
lular mechanisms of seizure genesis caused by different SCN1A
mutations [73]. Heterologous expression systems, in which cloned
sodium channel -subunits are expressed in an intrinsically non-
excitable cell, were the ﬁrst models used to investigate the cellular
consequences of SCN1A mutations associated with epilepsy. Stud-
ies in heterologous systems were the ﬁrst to demonstrate that
SCN1A mutations can cause both gain and loss of function at the
channel level [74]. There is now growing evidence that epilep-
togenic SCN1A mutations cause mainly loss of function, whereas
gain of function is found for mutations that cause familial hemi-
plegic migraine [75]. Heterologous expression systems have been
used for testing compounds that modulate voltage-gated sodium
channels. For example, ranolazine, a U.S. Food and Drug Admin-
istration (FDA)-approved drug for chronic angina treatment, was
ﬁrst identiﬁed as a selective blocker of persistent currents in mutant
NaV1.1 channels expressed in one of these models [76]. In follow-up
studies in cultured rat hippocampal neurons, ranolazine was found
to reduce neuronal excitability and suppress epileptiform activ-
ity evoked by NMDA receptor activation [77]. A more recent study
showed that ranolazine does not inhibit the persistent Na+ current
more strongly than phenytoin in central neurons, but is a better
use-dependent blocker of transient Na+ current than phenytoin
[78]. Furthermore, identifying compounds that can differentially
modulate different subtypes/isoforms of sodium channels may
contribute to identifying new treatment strategies for SCN1A-
related epilepsy [79]. Mouse models have shown how the same
SCN1A mutation can have differential effects on different types of
neurons, and how the same type of mutation, such as SCN1A trunca-
tions, may  have different effects on neuronal excitability depending
on developmental stage [65,80].
Baraban et al. [81] characterised zebraﬁsh Nav1.1 (scn1Lab)
mutants originally identiﬁed in a chemical mutagenesis screen
using the optokinetic response as an assay [82]. The zebraﬁsh
scn1Lab gene shares a 77% identity with human SCN1A and is
expressed in the central nervous system. Baraban et al. [81] demon-
strated that mutants exhibit hyperactivity, including convulsive
behaviour, spontaneous electrographic seizures, shortened lifes-
pan and a pharmacological proﬁle similar to the human condition.
They then used the validated model in a novel high-throughput
screening program to identify compounds that ameliorated theya, Pharmacogenomics in epilepsy, Neurosci. Lett. (2017),
epilepsy phenotype. The strategy identiﬁed clemizole, a US Food
and Drug Administration (FDA)-approved compound but not a
licensed AED, as an effective inhibitor of spontaneous convulsive
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een no further reports on clemizole use in Dravet Syndrome or
odels. Recent data suggest that fenﬂuramine may  be effective in
ravet syndrome [83,84]. This drug was initially developed as an
ppetite suppressant, but withdrawn from the market due to seri-
us adverse effects, including valvular heart disease and pulmonary
ypertension [85,86]. Fenﬂuramine has serotoninergic effects [87],
ut the exact anti-seizure mechanism has not been elucidated
et. Fenﬂuramine signiﬁcantly reduced epileptiform discharges in
cn1Lab morphants in recent studies [88,89]. Currently there are
our ongoing clinical trials to evaluate the effectiveness and toler-
bility of this drug in Dravet Syndrome. A functional link between
he serotonergic and GABAergic pathway has recently been elu-
idated since 5-HT2A agonism elevates the activity of GABAergic
nterneurons [90]. A recent study in zebraﬁsh suggested a dual
echanism in Dravet Syndrome pathophysiology, postulating that
ABA interneurons are defective, not only due to presence of muta-
ions but also by a relative deﬁciency in locally released serotonin
91]. If conﬁrmed, this supports serotonergic receptor modulation
s a promising therapeutic target in Dravet Syndrome.
Some patients with Dravet Syndrome have seizure aggravation
ith exposure to sodium channel blockers, e.g. carbamazepine,
amotrigine and phenytoin [92]. As Nav1.1 shows higher expression
n inhibitory bipolar as compared to excitatory pyramidal neu-
ons [93], it can be hypothesized that the effect of sodium channel
lockers on already impeded inhibitory interneurons outweighs
he effect on excitatory neurons leading to a further decrease in
nhibition and seizure exacerbation. However, it has been shown
ow lamotrigine can improve seizure control in some patients
ith Dravet Syndrome [94]. All these ﬁndings show how treatment
esponse maybe speciﬁc to the nature and the location of the SCN1A
utation [75,95], and offers up a somewhat daunting perspective
f precision medicine in the epilepsies.
The NMDA receptor is a ligand-gated ion channel activated
y glutamate. GRIN2A encodes a subunit of the NMDA receptor.
utations and deletions in the GRIN2A gene predispose to several
hildhood-onset epilepsy syndromes within the epilepsy-aphasia
pectrum, including Landau-Kleffner syndrome (LKS), epileptic
ncephalopathy with continuous spike-and-wave during sleep
ECSWS), childhood epilepsy with centrotemporal spikes (CECTS),
typical childhood epilepsy with centrotemporal spikes (ACECTS),
utosomal dominant rolandic epilepsy with speech dyspraxia
ADRESD), and infantile-onset epileptic encephalopathy [96–100].
nder normal conditions of synaptic transmission, very few ions
ass through the channel because magnesium (Mg2+) blocks the
ore. Upon receptor activation, Mg2+ is displaced, which allows
alcium (Ca2+) and other cations to move into the cell. A dysfunc-
ional NMDA receptor can allow excess calcium inﬂux into the cell.
n vitro experiments testing activity of a GRIN2A mutant (L812 M)
eceptor showed increased activity in response to agonists and
ecreased response to negative modulators [101]. In vitro analysis
howed that memantine, a N-methyl-d-aspartate (NMDA) receptor
ntagonist, inhibited the increased activity of the NMDA receptor
aused by the L812 M mutation. A child with an early onset epilep-
ic encephalopathy due to this GRIN2A missense mutation (L812 M)
102] was treated with memantine added on to his antiepileptic
edication regimen, and had a signiﬁcant decrease in seizure fre-
uency and improvement in interictal EEG recordings. In contrast,
nother child’s epileptic encephalopathy was found to be caused by
 different GRIN2A missense mutation (N615 K) causing a different
hannel dysfunction, with no effect on receptor activity, but acting
hrough the relief of Mg2+ blockade [96]. Treatment with meman-
ine was therefore not tried in this case, as it was  not indicated.Please cite this article in press as: S. Balestrini, S.M. Sisodi
http://dx.doi.org/10.1016/j.neulet.2017.01.014
A child with a different epilepsy syndrome, migrating partial
eizures of infancy (an early onset epileptic encephalopathy syn-
rome which is typically drug-resistant), due to a gain of function
utation in the gene KCNT1,  was treated with the antiarrhyth- PRESS
nce Letters xxx (2017) xxx–xxx 5
mic  drug quinidine. This drug is a partial antagonist of KCNT1,
and the treatment was  associated with a marked reduction in
seizure frequency and improved psychomotor development [103].
Quinidine was previously used to reverse the hyperactivity of the
mutant KCNT1 in Xenopus oocytes [104]. A second case with KCNT1-
related epilepsy, showing a novel phenotype with developmental
regression and severe nocturnal focal and secondarily generalised
seizures starting in early childhood, did not respond to treatment
with quinidine [105]. Currently the therapeutic effects of quinidine
in KCNT1-related epilepsy remain largely unknown and more work
is required, although it seems a promising treatment option due to
gain-of-function mutations in KCNT1.
KCNQ2-related epilepsy is another example where a molec-
ular diagnosis may  inﬂuence the therapeutic choice. Retigabine
(ezogabine), is a drug primarily acting as a positive allosteric
modulator of KCNQ2-5 (Kv7.2–7.5) ion channels: it is the ﬁrst neu-
ronal potassium (K + ) channel opener licensed for the treatment
of epilepsy [106]. In vitro studies identiﬁed the probable bind-
ing site of retigabine in KCNQ2 and KCNQ3 channels, explaining
its voltage-dependent activating effect through a hyperpolarizing
shift of the activation curve [107,108]. KCNQ2 and KCNQ3 mutations
have been associated with a phenotypic spectrum ranging from a
benign form of neonatal epilepsy (BFNS) [109] to a severe form of
early-onset epileptic encephalopathy [110,111]. Orhan et al. [112]
deﬁned the disease mechanism of seven de novo missense KCNQ2
mutations associated with severe epileptic encephalopathy and
found a clear loss of function for all the mutations studied in vitro.
Most mutations showed a dominant-negative effect on wild-type
KCNQ2 or KCNQ3 subunits. The use of retigabine partially reversed
the loss of function, in vitro, for the majority of analyzed muta-
tions. Preliminary data from humans with KCNQ2-related disease
suggest retigabine may  be a useful treatment option [113], but more
data are required. Sodium channel blockers also seem effective
in KCNQ2-related epilepsy [111,114], possibly because voltage-
gated sodium channels and KCNQ potassium channels co-localize
and are bound at critical locations of the neuronal membrane
[115]; modulation of one channel may  signiﬁcantly affect the func-
tion of the channel complex and this may  explain the efﬁcacy of
sodium-channel blockers that have a modulating effect on both
channels [111]. Sodium channel blockers including carbamazepine
and phenytoin should also be considered as ﬁrst-line treatment in
patients with KCNQ2-related epilepsy [116].
SCN2A encodes the alpha2 subunit of the neuronal sodium chan-
nel and has also been associated with a wide phenotypic spectrum
of epilepsy syndromes ranging from benign familial neonatal-
infantile seizures to epilepsy of infancy with migrating focal
seizures or other severe epileptic encephalopathies [117–119].
Sodium channel blockers have shown signiﬁcant effectiveness in
SCN2A-epileptic encephalopathies. The mechanism of the effect
has not been elucidated yet, but, as might be expected, the effect
seems mostly present in patients with gain-of-function mutations
[118,119]. An anecdotal case with a de novo SCN2A splice site
mutation associated with epileptic encephalopathy, early onset
global developmental delay, intermittent ataxia, autism, hypotonia,
and cerebral/cerebellar atrophy was  recently reported. In the cere-
brospinal ﬂuid, both homovanillic acid and 5-hydroxyindoleacetic
acid were signiﬁcantly decreased; extensive biochemical and
genetic investigations ruled out primary neurotransmitter deﬁ-
ciencies and other known inborn errors of metabolism. Treatment
with oral 5-hydroxytryptophan, l-Dopa/Carbidopa, and a dopa ago-
nist resulted in mild improvement of seizure control, most likely
via dopamine and serotonin receptor activated signal transductionya, Pharmacogenomics in epilepsy, Neurosci. Lett. (2017),
and modulation of glutamatergic, GABA-ergic and glycinergic neu-
rotransmission [120]. This single case hints at the complexity that
is likely to be observed when additional or compensatory changes
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SCN8A encodes the voltage-dependent sodium channel Nav1.6,
ocated in both inhibitory and excitatory neurons [121]. Mutations
n this gene have been found in 0.6-2.4% of cases with early infan-
ile epileptic encephalopathy [122,123] and have been associated
ith increased risk of SUDEP [121,123–125]. In most cases, SCN8A
utations occurred de novo and showed a gain-of-function effect
121,126]. There is clinical evidence of a possible effective preci-
ion medicine approach in using sodium channel blockers to treat
atients with SCN8A-related epilepsy [121,123,127], in particular if
he mutations are known to cause gain of function [128].
Tuberous sclerosis complex (TSC) is an autosomal dominant,
ulti-organ disease with widely variable clinical expression.
pproximately 85% of patients with TSC are found to have a muta-
ion in one of two genes, TSC1, encoding hamartin, or TSC2, encoding
uberin [129]. Protein products of these genes have been shown to
orm a heterodimer (TSC1–TSC2 complex) that inhibits the mech-
nistic target of rapamycin (mTOR) signaling cascade [130]. The
TOR signaling cascade regulates processes involved in cell growth
nd homeostasis in response to many metabolic cues. Dysregu-
ated, inadequate suppression of the mTOR pathway results in
ysplastic lesions in multiple organ systems, including cortical
ubers, radial glial bands, subependymal nodules, and subependy-
al  giant cell tumor formation in the fetal and developing brain
131]. Epilepsy is the most common neurologic symptom in
atients with TSC [132]. Rapamycin (otherwise known as sirolimus)
s an inhibitor of mTOR. Rapamycin prevents activation of T cells
nd B cells by inhibiting their response to interleukin-2 (IL-2), and
s an FDA-approved drug for immunosuppression after organ trans-
lantation. A clinical trial of rapamycin for renal angiomyolipomata
ssociated with tuberous sclerosis or lymphangioleiomyomatosis
evealed an almost 50% decrease in angiomyolipoma volumes by
he end of the 12-month rapamycin administration period [133].
 phase 2 multicenter trial was conducted to evaluate the efﬁcacy
nd tolerability of sirolimus for the treatment of kidney angiomy-
lipomata [134]. Treatment with sirolimus for 52 weeks induced
egression of kidney angiomyolipomata, subependymal giant cell
strocytomas, and liver angiomyolipomata. Another clinical trial
as designed to study the impact of everolimus (a derivative of
irolimus) on subependymal giant cell astrocytoma growth and
howed sustained effect on tumor reduction over ≥5 years of
reatment, with no safety concerns [135,136]. Treatment with
apamycin was shown to prevent the development of epilepsy and
remature death in mouse models of TSC [137,138]. A few reports in
umans have showed signiﬁcant improvement in seizure control in
hildren and adults with TSC-associated epilepsy, with a tolerable
afety proﬁle [139–141]. More studies are needed, and are impor-
ant as evidence grows for a more widespread dysregulation of the
TOR pathway beyond that seen in TSC alone. One example comes
rom epilepsies due to mutation in a gene in this pathway.
DEPDC5 (Dishevelled, Egl-10 and Pleckstrin Domain Containing
rotein 5) loss-of-function mutations have recently been reported
n a variety of genetic focal epilepsy syndromes, including famil-
al focal epilepsy with variable foci, autosomal dominant nocturnal
rontal lobe epilepsy, familial temporal lobe epilepsy [142–144],
olandic epilepsy and other non-lesional focal childhood epilepsies
145] and focal epilepsy associated with focal cortical dysplasia,
oth familial and sporadic [146,147]. DEPDC5 variants have also
een found in cases with malformation of cortical development
146,147] and in one sporadic case with focal epilepsy among a
ohort of French-Canadian individuals [148]. DEPDC5 encodes a
rotein that is expressed ubiquitously in developing and adult
rain [142]; it has GTPase-activating protein (GAP) activity and isPlease cite this article in press as: S. Balestrini, S.M. Sisodi
http://dx.doi.org/10.1016/j.neulet.2017.01.014
art of the GATOR1 complex, a negative regulator of the mech-
nistic target of rapamycin complex 1 (mTORC1), in the mTOR
athway [149]. The mTORC1 pathway is dysregulated in sev-
ral neurological disorders associated with cortical malformations PRESS
nce Letters xxx (2017) xxx–xxx
and drug-resistant epilepsy, such as tuberous sclerosis [150] and
hemimegalencephaly [151]. Because DEPDC5 acts as a repressor of
mTOR activity, DEPDC5 mutations are predicted to result in upreg-
ulation of the mTOR signaling pathway. Prenatal treatment with
rapamycin in global Depdc5 knockout rats rescued growth delay
and embryonic lethality, and prevented enhanced cell size and
dysmorphism of neurons [152]. Disruption of the mTOR signaling
pathway is a putative pathophysiologic mechanism of epilepto-
genesis in different models of lesional epilepsy in rodents and
humans [153] and has emerged as a possible therapeutic target
for epilepsy [154]. Deep whole-exome sequencing identiﬁed muta-
tions of the MTOR gene in 12 of 77 subjects with focal cortical
dysplasia type II (FCDII), a sporadic developmental malformation
of the cerebral cortex characterised by dysmorphic neurons, dys-
lamination and medically-refractory epilepsy [155]. The identiﬁed
mutations induced the hyperactivation of mTOR kinase. Focal cor-
tical expression of mutant mTOR by in utero electroporation in
mice was sufﬁcient to disrupt neuronal migration and cause spon-
taneous seizures and cytomegalic neurons. Inhibition of mTOR with
rapamycin suppressed cytomegalic neurons and epileptic seizures,
so identifying mTOR as a treatment target for intractable epilepsy
in focal cortical dysplasia [155]. Germline heterozygous mutations
in the genes encoding the two other components of GATOR1, NPRL2
(nitrogen permease regulator-like 2), and NPRL3 (nitrogen perme-
ase regulator-like 3), have been reported. An NPRL3 pathogenic
mutation was  discovered by whole exome sequencing in a fam-
ily including four subjects with focal epilepsy, two of whom had
focal cortical dysplasia type IIa, and later identiﬁed in two addi-
tional unrelated patients with focal cortical dysplasia type IIa [156].
A second study using whole exome sequencing in a large fam-
ily with autosomal dominant nocturnal epilepsy without apparent
structural brain abnormalities uncovered an inactivating variant
in NPRL2 [157]. Two other studies identiﬁed several NPRL2 and
NPRL3 mutations in both sporadic and familial focal epilepsies using
targeted gene panel sequencing [158,159]. GATOR1 complex gene
mutations leading to mTORC1 pathway upregulation are an impor-
tant cause of focal epilepsy with cortical malformations. Treatment
with mTOR inhibitors in patients with gene mutations affecting
the GATOR1 complex subunit has not yet been investigated to our
knowledge. However pathophysiological similarities between dif-
ferent mTORopathies warrant further studies [146].
PRICKLE proteins, such as PRICKLE1, are core constituents of
the planar cell polarity signaling pathway that establishes cell
polarity during embryonic development [160]. Mutations in the
PRICKLE genes can cause seizures in humans, zebraﬁsh, mice,
and ﬂies, suggesting a seizure-suppression pathway that may
be evolutionarily conserved [161,162]. This pathway has never
been targeted for novel anti-seizure treatments. Paemka et al.
[163] deﬁned the mammalian PRICKLE-interactome, identifying
PRICKLE-interacting proteins that localize to synapses and a novel
interacting partner, USP9X, a substrate-speciﬁc de-ubiquitinase.
Their ﬁndings demonstrated that inhibition of USP9X can arrest
PRICKLE-mediated seizures. As PRICKLE mutant humans, mice,
zebraﬁsh, and Drosophila all exhibit seizures [162,164], USP9X-
modulating molecules may  be worth pursuing as a new class of
anti-seizure therapy. This represents an example of the transla-
tional power of studying diseases in species across the evolutionary
spectrum.
Based on all these reports, the ascertainment of a molecu-
lar diagnosis early in life and generation and characterization of
cell culture and valid animal models for the interpretation of the
functional consequences of a mutation, may become fundamen-ya, Pharmacogenomics in epilepsy, Neurosci. Lett. (2017),
tal for overall diagnosis, prognosis and therapeutic management.
Currently, genetically-targeted therapies are available for only a
minority of genetic epilepsies. Such therapies include drugs that
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rovide alternative energy supply to the brain by avoiding defec-
ive transport mechanisms. So far, drugs or treatment that have
een investigated were those already available on the market but
ot necessarily approved for the treatment of epilepsy. Novel drug
eneration has yet to come.
.1. Inﬂuence of genetic factors on adverse drug reactions
Genetic polymorphisms have been associated with the risk of
ide effects. In particular, there is extensive evidence of the associ-
tion between certain human leukocyte antigen (HLA) alleles and
ncreased risk of idiosyncratic adverse drug reactions.
. Established evidence
A strong association was found in people with epilepsy and
an Chinese origin between a genetic marker, HLA-B*15:02, and
tevens-Johnson syndrome induced by treatment with carba-
azepine, probably due the role of this allele in mediating the
ctivation of cytotoxic T-lymphocytes [165,166]. The frequency of
he HLA-B*15:02 allele is very low in Caucasian people, but high
n Han Chinese and other South Asian ethnic groups, including
eople from Thailand, Malaysia, Vietnam and other South Asian
ountries: the risk of HLA-B*15:02-associated Stevens-Johnson
yndrome and toxic epidermal necrolysis is dependent on the
peciﬁc population. A study conducted in Taiwan showed that
creening patients for the HLA-B*15:02 allele before the initia-
ion of carbamazepine treatment and withholding carbamazepine
rom HLA-B*15:02–carrying patients can reduce the incidence of
arbamazepine-induced Stevens-Johnson syndrome and toxic epi-
ermal necrolysis among patients of Han Chinese origin [167].
egulatory agencies and therapeutic guidelines recommend that
atients from Han Chinese and other South Asian ethnic groups
e genotyped for HLA-B*15:02 before commencing treatment with
arbamazepine, and that carbamazepine be avoided if at all pos-
ible in carriers of this allele [168,169]. The HLA-B*15:02 allele
as also been associated with increased risk of Stevens-Johnson
yndrome/toxic epidermal necrolysis after treatment with other
romatic AEDs, including phenytoin [170], oxcarbazepine [171],
nd lamotrigine [170]. This is the best example of a useful phar-
acogenetic variant in epilepsy.
HLA-A*31:01 has been associated with increased risk of
arbamazepine-induced hypersensitivity reactions, ranging from
aculopapular exanthema to severe blistering reactions, among
ubjects of European ancestry and in the Japanese population
172,173]. Recent economic modelling suggested that routine test-Please cite this article in press as: S. Balestrini, S.M. Sisodi
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ng for HLA-A*31:01 in order to reduce the incidence of cutaneous
dverse drug reactions in patients being prescribed carbamazepine
or epilepsy is likely to represent a cost-effective use of health care
esources [174].
able 1
nﬂuence of genetic factors on response and adverse reactions to AEDs through various m
Response
Mediator Genetic factor Ef
Pharmacokinetics and
pharmacodynamics
Variation in CYP2C9 gene Ri
[1
Variation in CYP2C19 gene As
cli
Variation in CYP2C19 gene Et
UGT1A1 variants Al
Variation in CYP2C19 gene Ri
Variation in SCN1A, ABCC2, UGT2B7 genes As
Variation in CYP1A1 gene As
ABCB1 gene (encoding P-glycoprotein,
P-gp, multidrug transporter) variants
Dr
Variation in genes coding for AED targets No PRESS
nce Letters xxx (2017) xxx–xxx 7
8. Unclear evidence
In some patients treated with VPA, severe hyperammone-
mia  has been observed in the absence of liver failure and may
result in encephalopathy with the following symptoms: vom-
iting, ataxia, behavioural changes, lethargy, somnolence, or, in
extreme cases, coma [175]. The exact mechanism of VPA-induced
encephalopathy has not been fully deﬁned yet. A prospective
multi-center study evaluated the putative association between the
T1405 polymorphism in the carbamoyl phosphate synthetase 1
(CPS1) gene and occurrence of VPA-induced hyperammonemia in
a cohort of 142 adult Caucasian patients with epilepsy treated
with valproic acid for at least one year and with normal liver
function. They found that this variant was  a signiﬁcant risk fac-
tor for the occurrence of hyperammonemia, even in patients with
serum VPA levels within a speciﬁed therapeutic range [176]. Non-
alcoholic fatty liver disease is another adverse reaction that can be
induced by VPA treatment [177] and this chronic liver condition
is associated with elevated serum levels of -glutamyltransferase
(-GT) [178]. A retrospective study in Japanese patients showed
that the Val16Ala polymorphism of the Superoxide Dismutase
2 (SOD2) gene, encoding an antioxidant enzyme with a criti-
cal role in the detoxiﬁcation of mitochondrial reactive oxygen
species, has an impact on the relationship between VPA exposure
and -GT elevation. This was determined by using a population
pharmacokinetic-pharmacodynamic modelling approach [179].
Weight gain, a common adverse reaction of VPA, has been associ-
ated with leptin receptor (LEPR) and ankyrin repeat kinase domain
containing 1 (ANKK1) gene polymorphisms in a cohort of Han Chi-
nese people with epilepsy [180]. All these ﬁndings need replication.
Although the mechanism of VPA-induced adverse effects is
not clearly understood, there is evidence that its metabolic pat-
tern is associated with the pathogenesis of adverse drug reactions.
VPA-induced liver damage has been associated with CYP2C9-and
CYP2A6-mediated formation of the hepatotoxic 4-ene metabo-
lite [181]. In a paediatric cohort, Budi et al. [182] found that
CYP2C9 variant-guided treatment signiﬁcantly reduced valproic
acid misdosing. In the group of children (n = 52) who  received a
CYP2C9-status adapted dose, signs of toxicity, notably hyperam-
monemia, were reduced. These ﬁndings, as many others in epilepsy
pharmacogenetics, still require replication.
There are other studies of genetic factors associated with
adverse drug reactions, with unclear evidence. We  made an
arbitrary selection of some of the most recent or potentially clin-
ically relevant studies. Additional studies can be found listed on
the Epilepsy Genetic Association Database (epiGAD; http://www.ya, Pharmacogenomics in epilepsy, Neurosci. Lett. (2017),
epigad.org/).
A summary of all the ﬁndings presented is reported in Table 1.
ediators: summary of existing ﬁndings.
fect [references]
sk of developing concentration-dependent neurotoxicity from phenytoin
2,13]- established evidence
sociation with the serum concentration of N-desmethylclobazam and with its
nical efﬁcacy, indicating a gene-dose effect [17–21]
hnic differences in the tolerability proﬁle of phenobarbital [22]
tered clearance of lamotrigine [25]
sk of adverse reactions from zonisamide [28]
sociation with oxcarbazepine maintenance doses [36]
sociation with response to ﬁrst-line antiepileptic drugs in Indian women [37,38]
ug-resistant epilepsy [40–45]
 signiﬁcant association with drug response [49–53]
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Table  1 (Continued)
Response
Mediator Genetic factor Effect [references]
Epilepsy genes Mutations in the SLC2A1 gene causing
GLUT-1 deﬁciency syndrome
Gold standard treatment is the ketogenic diet, treating the symptoms of
neuroglycopenia [57–59]- established evidence
Bi-allelic mutations in the ALDH7A1 gene
causing pyridoxine (vitamin
B6)-dependent epilepsy
Gold standard treatment is pyridoxine or pyridoxal 5′-phosphate supplementation
[60,61]- established evidence
SCN1A-related epilepsies Stiripentol is effective in Dravet Syndrome (especially when combined with
valproate and clobazam), established in a randomised controlled trial; however,
the  use of stiripentol, valproate and clobazam does not always yield complete
seizure freedom and may  cause adverse side effects [70–72]
Ranolazine was identiﬁed as a selective blocker of persistent currents in mutant
NaV1.1 channels expressed in heterologous expression systems [76–78]-
uncertain evidence, recently it was shown that ranolazine does not inhibit the
persistent Na+ current more strongly than phenytoin in central neurons
Clemizole was  identiﬁed as an effective inhibitor of spontaneous convulsive
behaviour and electrographic seizures in zebraﬁsh Nav1.1 (scn1Lab) mutants [81]
Fenﬂuramine has serotoninergic effects and was  shown to signiﬁcantly reduce
epileptiform discharges in scn1Lab morphants. Evidence of effectiveness in control
of  convulsive seizures and good tolerability in a small cohort of patients with
Dravet Syndrome [83–89]- ongoing clinical trials in Dravet syndrome
Use of sodium channel blockers can aggravate seizures in Dravet syndrome. Note,
however, that lamotrigine can improve seizure control in some patients with
Dravet Syndrome [92,94]
GRIN2A causing early-onset epileptic
encephalopathy
Use of memantine, a N-methyl-d-aspartate (NMDA) receptor antagonist, can
inhibit the increased activity of the NMDA receptor caused by speciﬁc mutations
[102]
KCNT1-related epilepsy Use of quinidine, partial antagonist of KCNT1 used as antiarrhythmic drug, was
shown to reduce seizure frequency and improve psychomotor development in one
patient with migrating partial seizures of infancy [103] and was  shown to reverse
the  hyperactivity of mutant KCNT1 in Xenopus oocytes [104]
KCNQ2-related epilepsies Use of retigabine (ezogabine), a positive allosteric modulator of KCNQ2-5
(Kv7.2–7.5) ion channels, was shown to partially reverse the loss of function, in
vitro, of missense KCNQ2 mutations associated with severe epileptic
encephalopathy [107,108,113]- only preliminary data in humans
Sodium channel blockers seem effective in KCNQ2-related epilepsy, possibly
because voltage-gated sodium channels and KCNQ potassium channels co-localize
and are bound at critical locations of the neuronal membrane [111,114–116]
SCN2A-related epilepsies Sodium channel blockers have shown signiﬁcant effectiveness in SCN2A-epileptic
encephalopathies; pathophysiological considerations suggest that sodium channel
blockers should only be applied in patients with gain-of-function mutations
[118,119]
Treatment with oral 5-hydroxytryptophan, l-Dopa/Carbidopa, and a dopa agonist
resulted in mild improvement of seizure control, in a case with a de novo SCN2A
splice site mutation associated with epileptic encephalopathy [120]
SCN8A-related epilepsies Sodium channel blockers have shown effectiveness in patients with
gain-of-function mutations; in rare cases an apparent loss-of-function effect has
been described but it remains unclear if these may show gain-of-function effect
in  vivo [121,123,127,128]
Tuberous sclerosis complex (TSC)
associated with TSC1 or TSC2 mutations
Rapamycin (sirolimus), an inhibitor of the mechanistic target of rapamycin
(mTOR) signaling cascade, was shown to prevent the development of epilepsy and
premature death in mouse models of TSC and to signiﬁcantly improve seizure
control in children and adults with TSC-associated epilepsy, with a tolerable safety
proﬁle [137–141]
DEPDC5-related epilepsies DEPDC5 encodes a protein that is part of the GATOR1 complex, a negative
regulator of the mechanistic target of rapamycin complex 1 (mTORC1), in the
mTOR pathway; its mutations are predicted to result in upregulation of the mTOR
signaling pathway. Inhibition of mTOR pathway with rapamycin was shown to
suppress cytomegalic neurons and epileptic seizures in model systems [152–154].
No  studies on treatment with mTOR inhibitors in patients with gene mutations
affecting the GATOR1 complex subunit
PRICKLE-mediated seizures USP9X, a substrate-speciﬁc de-ubiquitinase, is a partner in the mammalian
PRICKLE-interactome. Inhibition of USP9X can arrest PRICKLE-mediated seizures
[163]. No studies in humans
Adverse reactions
HLA-B*15:02 Stevens-Johnson syndrome and toxic epidermal necrolysis induced by
carbamazepine and other aromatic AEDs in patients from Han Chinese and other
South Asian ethnic groups [165–170]- established evidence
HLA-A*31:01 Increased risk of carbamazepine-induced hypersensitivity reactions in patients of
European ancestry and in the Japanese population [172,173]- established evidence
T1405 polymorphism of the CPS1 gene Increased risk of valproate-induced hyperammonaemia in Caucasian patients
[176]
Val16Ala polymorphism of the SOD2 gene Elevated serum level of -glutamyltransferase induced by valproate in Japanese
patients [179]
Polymorphic LEPR and ANKK1 genes Weight gain on valproate in Han Chinese patients [180]
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.1. Future of pharmacogenomics: new paradigms for testing and
ranslation?
Recent advances in genetic testing are at the heart of cur-
ent research on the genetic factors inﬂuencing drug response and
dverse drug reactions in epilepsy. Genetic, and especially genomic,
esting is likely to be increasingly used to improve the effectiveness
nd safety of epilepsy treatments. Precision medicine treatments
epresent a new incarnation of the age-old physician’s paradigm
o consider treatment for each patient holistically: genetics may
ermit therapy directed at reversing or circumventing the patho-
hysiological effects of speciﬁc gene mutations. Precision medicine
ould transform clinical care in epilepsy in the form of a new treat-
ent framework and prognostic tools.
A systematic approach to precision medicine in epilepsy should
e based on: large cohorts of people with epilepsy with deep
enotype-phenotype correlations; standardised functional char-
cterisation of gene mutations which have had frequency and
ypes determined in cases and controls; and the initiation of well-
esigned innovative clinical trials of targeted treatments identiﬁed
hrough functional work. This will require new and more intensive
ollaborations and integrated research groups that bring together
esearchers with clinical, genetic, pharmacological and biological
xpertise.
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